The pharmaceutical industry has set off a wave of AI research and development, and it will also have great prospects in the pharmaceutical field

[Pharmaceutical Network Market Analysis] With the help of AI pharmaceuticals, it can improve the speed of new drug research and development and reduce costs, and help pharmaceutical companies to speed up innovation and transformation, reduce costs and increase efficien.
Therefore, in order to accelerate the development of new drugs, pharmaceutical companies have begun to act in the field of AI in recent yea.
frequent.
 The pharmaceutical industry has set off a wave of AI research and development, and it will also have great potential in the pharmaceutical field (Photo source: Pharmaceutical Network) For example, Yunnan Baiyao recently announced that it has signed a cooperation agreement with Huawei to carry out extensive exchanges and cooperation in the field of artificial intelligence drug research and development, including Large and small molecule design, related diseases, database development,e.
In addition, at the beginning of this year, Shanghai Fosun Pharma and Insilico Medicine, an end-to-end artificial intelligence-driven drug R&D company, also announced a cooperation agreement to jointly promote the R&D of AI drugs for multiple targets on a global scale… … On the whole, with the continuous development of AI technology and the increasing attention paid to it by pharmaceutical companies, AI has been widely used in all stages of drug research and development, mainly in the two stages of drug discovery and clinical resear.
Diseases are mainly cancer, mental and cardiovascul.
Faster progressing AI drugs are already on the market, but more are still in the early stage of development, among which there are a large number of cancer pipelines; followed by neurological diseases, intestinal diseases, e.
; in addition, some companies have deployed genetic diseases and Rare disease and other niche trac.
It is understood that the fastest-growing AI drug development in China is ISM001-055 of Insilico Medici.
ISM001-055 is a drug candidate discovered by Phar.
AI, an end-to-end artificial intelligence drug development platfo.
It is a new small molecule inhibitor targeting a new target and is being developed for the treatment of idiopathic pulmonary fibros.
In 2021, Insilicon announced the discovery of a new target ISM001-055, which took only 18 months and invested US$6 million, and the research cost was 10% of the traditional o.
Then in November 2021, the drug entered the phase I clinical trial in Austral.
Industry analysts believe that although the field of AI pharmacy is still in the early stage of development, no drug has been successfully launched y.
However, AI pharmaceuticals has obviously been regarded as a breakthrough in the industry, which will help pharmaceutical companies to improve the efficiency and success rate of new drug research and development, help drug research and development technology upgrade and reform, and empower Chinese pharmaceutical companies to innovate at the sour.
In the future, with the continuous help of AI technology and platforms, people are expected to halve the risks related to drug development and discovery, and at the same time, the layout of pharmaceutical companies will also usher in more new breakthroughs in innovati.

From the current point of view, the domestic AI pharmaceutical track will continue to be h.

In this regard, some industry insiders have proposed that in addition to the pharmaceutical field, the integration of AI and the pharmaceutical equipment industry will also be further accelerat.

In the future, whether it is in equipment innovation or management, e.

All aspects will play an important ro.

In fact, many pharmaceutical equipment companies have begun to join the exploration of AI + pharmaceutical equipme.

For example, many companies are concentrating on promoting the production model of "robots instead of manual labor", using Internet technology, Internet of Things technology, automated logistics systems and other technologies to innovate and upgrade traditional process.

At present, under the active practice of relevant enterprises, the results have begun to appe.

For example, a sterile robot developed by a pharmaceutical machine company can automatically complete the unpacking and material transfer of prefilled syringes, and integrate film tearing, inner paper removal, filling, and stopperi.

This not only greatly reduces the probability of drug contamination, but also enables the entire production cycle of drugs to be digitized and traceable throughout the proce.
In addition, there are compressor manufacturers that use full digital traceability systems, smart sensors, visual inspection, and automatic monitoring systems to help pharmaceutical companies improve their production quality control systems and increase labor productivity by 3
In general, AI is gradually becoming a new breakthrough in promoting the high-quality development of the pharmaceutical equipment industry, which continues to have an impact on technological innovation, management, and syste.

In the future, with the continuous improvement of AI technology, the industry predicts that the technological transformation and optimization and upgrading of the pharmaceutical equipment industry will continue, and less labor and unmanned production, and dual-intelligent production models will become the general trend of the indust.

Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.